Attovia Therapeutics, Inc.
corporate_fare Company Profile
Attovia Therapeutics, Inc. (NASDAQ:ATTO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 6 items for ATTO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-02, rated 7/10. Across its 6 most recent items scored 7 or higher, the top rating is 8/10, with 4 rated 8 or above. Recent SEC coverage for ATTO spans 10-Q, 4/A, 4, SCHEDULE 13D.
Recent high-impact activity:
- Attovia Reports Q2 2026 Loss of $20.7M; IPO Proceeds Extend Runway into 2030
- Attovia's ATTO-1310 Shows Clinical Proof of Concept; Cash Runway Extended to 2030
- Director Colin Walsh's Amended Form 4 Reveals $12.5M Purchase and Previously Undisclosed Equity Swaps
- Director Colin Walsh Buys $8.5M of Attovia Stock at $17, Sells $2.25M
- Frazier Life Sciences Builds 15.3% Stake in Attovia Therapeutics After IPO, Adding $3.3M in Open Market Buys
Short Interest & Short Volume
4.01 days to coverFINRA reported short interest of 831,090 shares in ATTO as of the September 15, 2026 settlement, a 28.2% increase from the prior period — about 4.0 days to cover at its recent average daily volume. On October 2, 2026, 59.5% of ATTO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.